进展性特发性肺纤维化的生物标志物特征
研究在三个独立IPF队列中评估血清生物标志物的预后作用,通过LASSO回归筛选并在验证队列中复制,构建基于四个生物标志物三分位数的进展指数模型,发现该指数可预测进展、死亡和无进展生存,且在部分队列中优于GAP评分。
要点
- 骨桥蛋白、MMP-7、ICAM-1和骨膜蛋白四个血清标志物在进展表型中显著复制。
- 基于四分位数的进展指数可预测IPF患者进展、死亡和无进展生存。
- 进展指数联合模型在部分队列中优于GAP评分区分12个月疾病进展。
核心结论
- 循环生物标志物组合可为IPF患者预后提供有价值的临床辅助。
研究设计与样本
- 研究纳入三个独立IPF队列:AIPFR队列189人、TLF队列205人、PROFILE队列122人。
- 在AIPFR队列用ELISA和无偏蛋白质组学评估候选蛋白,LASSO回归筛选进展表型标志物。
- 筛选标志物在TLF队列前瞻性复制,在PROFILE队列回顾性评估。
主要发现
- ELISA显示骨桥蛋白、MMP-7、ICAM-1和骨膜蛋白在1年进展表型患者中差异表达并复制。
- 蛋白质组学数据未复制。
- 进展指数在三个队列中预测进展风险、死亡和无进展生存。
- 包含进展指数的统计模型可区分12个月疾病进展,在所有队列中优于GAP评分模型,在TLF和PROFILE队列中差异显著。
关键数值与推荐
- 四个显著复制的生物标志物基于循环浓度三分位数聚合为进展指数模型。
临床怎么用
- 血清生物标志物组合可能辅助IPF患者预后评估和临床管理。
局限性
- 蛋白质组学数据未复制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which circulatory biomarkers have the potential for guiding management in clinical practice. We assessed the prognostic role of serum biomarkers in three independent IPF cohorts: Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR), Trent Lung Fibrosis (TLF) and Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE). METHODS: In the AIPFR cohort, candidate proteins were assessed by ELISA as well as in an unbiased proteomic approach. LASSO (least absolute shrinkage and selection operator) regression was used to restrict the selection of markers that best accounted for the progressor phenotype at 1 year in the AIPFR cohort, and subsequently prospectively selected for replication in the validation TLF cohort and assessed retrospectively in the PROFILE cohort. Four significantly replicating biomarkers were aggregated into a progression index model based on tertiles of circulating concentrations. RESULTS: 189 participants were included in the AIPFR cohort, 205 participants from the TLF cohort and 122 participants from the PROFILE cohort. Differential biomarker expression was observed by ELISA and replicated for osteopontin, matrix metallopeptidase-7, intercellular adhesion molecule-1 and periostin for those with a progressor phenotype at 1 year. Proteomic data did not replicate. The progression index in the AIPFR, TLF and PROFILE cohorts predicted risk of progression, mortality and progression-free survival. A statistical model incorporating the progression index demonstrated the capacity to distinguish disease progression at 12 months, which was increased beyond the clinical GAP (gender, age and physiology) score model alone in all cohorts, and significantly so within the incidence-based TLF and PROFILE cohorts. CONCLUSION: A panel of circulatory biomarkers can provide potentially valuable clinical assistance in the prognosis of IPF patients.
引用
- Clynick B, Corte TJ, Jo HE, et al. Biomarker signatures for progressive idiopathic pulmonary fibrosis. Eur Respir J. 2022. PMID: 34675050. doi:10.1183/13993003.01181-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。